company background image
RHON

Rhone Ma Holdings Berhad KLSE:RHONEMA Stock Report

Last Price

RM0.69

Market Cap

RM152.6m

7D

-2.8%

1Y

0%

Updated

12 Aug, 2022

Data

Company Financials +
RHONEMA fundamental analysis
Snowflake Score
Valuation5/6
Future Growth0/6
Past Performance4/6
Financial Health5/6
Dividends2/6

RHONEMA Stock Overview

Rhone Ma Holdings Berhad, an investment holding company, engages in the manufacture, trading, marketing, and distribution of animal health products primarily in Malaysia.

Rhone Ma Holdings Berhad Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Rhone Ma Holdings Berhad
Historical stock prices
Current Share PriceRM0.69
52 Week HighRM0.79
52 Week LowRM0.67
Beta0.28
1 Month Change1.47%
3 Month Change-4.83%
1 Year Change0%
3 Year Change-4.17%
5 Year Change-36.75%
Change since IPO-12.76%

Recent News & Updates

May 02
Rhone Ma Holdings Berhad (KLSE:RHONEMA) Has Announced A Dividend Of RM0.01

Rhone Ma Holdings Berhad (KLSE:RHONEMA) Has Announced A Dividend Of RM0.01

Rhone Ma Holdings Berhad's ( KLSE:RHONEMA ) investors are due to receive a payment of RM0.01 per share on 15th of July...

Shareholder Returns

RHONEMAMY PharmaceuticalsMY Market
7D-2.8%-0.2%0.2%
1Y0%-3.9%-3.5%

Return vs Industry: RHONEMA exceeded the MY Pharmaceuticals industry which returned -4% over the past year.

Return vs Market: RHONEMA exceeded the MY Market which returned -3.4% over the past year.

Price Volatility

Is RHONEMA's price volatile compared to industry and market?
RHONEMA volatility
RHONEMA Average Weekly Movement4.1%
Pharmaceuticals Industry Average Movement3.9%
Market Average Movement5.5%
10% most volatile stocks in MY Market11.7%
10% least volatile stocks in MY Market2.7%

Stable Share Price: RHONEMA is not significantly more volatile than the rest of MY stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: RHONEMA's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2000n/aI-Ie Limhttps://www.rhonema.com

Rhone Ma Holdings Berhad, an investment holding company, engages in the manufacture, trading, marketing, and distribution of animal health products primarily in Malaysia. It operates through Animal Health Products, Food Ingredients, and Others segments. The company provides diagnostic laboratory analysis and consultation services to veterinary, agriculture, and food industries; veterinary advisory services; and distributes pharmaceutical and veterinary products, including animal feeds.

Rhone Ma Holdings Berhad Fundamentals Summary

How do Rhone Ma Holdings Berhad's earnings and revenue compare to its market cap?
RHONEMA fundamental statistics
Market CapRM152.65m
Earnings (TTM)RM11.71m
Revenue (TTM)RM177.92m

13.0x

P/E Ratio

0.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RHONEMA income statement (TTM)
RevenueRM177.92m
Cost of RevenueRM124.95m
Gross ProfitRM52.97m
Other ExpensesRM41.26m
EarningsRM11.71m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.053
Gross Margin29.77%
Net Profit Margin6.58%
Debt/Equity Ratio20.3%

How did RHONEMA perform over the long term?

See historical performance and comparison

Dividends

2.9%

Current Dividend Yield

35%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is RHONEMA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RHONEMA?

Other financial metrics that can be useful for relative valuation.

RHONEMA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.9x
Enterprise Value/EBITDA7x
PEG Ratio-3.5x

Price to Earnings Ratio vs Peers

How does RHONEMA's PE Ratio compare to its peers?

RHONEMA PE Ratio vs Peers
The above table shows the PE ratio for RHONEMA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average13.6x
YSPSAH Y.S.P. Southeast Asia Holding Berhad
15.3xn/aRM289.1m
PLABS PeterLabs Holdings Berhad
10xn/aRM53.7m
KOTRA Kotra Industries Berhad
10.4xn/aRM605.2m
DPHARMA Duopharma Biotech Berhad
18.9x7.8%RM1.3b
RHONEMA Rhone Ma Holdings Berhad
13x-3.7%RM152.6m

Price-To-Earnings vs Peers: RHONEMA is good value based on its Price-To-Earnings Ratio (13x) compared to the peer average (13.6x).


Price to Earnings Ratio vs Industry

How does RHONEMA's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?

Price-To-Earnings vs Industry: RHONEMA is good value based on its Price-To-Earnings Ratio (13x) compared to the MY Pharmaceuticals industry average (14x)


Price to Earnings Ratio vs Fair Ratio

What is RHONEMA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RHONEMA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio13x
Fair PE Ratio15.3x

Price-To-Earnings vs Fair Ratio: RHONEMA is good value based on its Price-To-Earnings Ratio (13x) compared to the estimated Fair Price-To-Earnings Ratio (15.3x).


Share Price vs Fair Value

What is the Fair Price of RHONEMA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: RHONEMA (MYR0.69) is trading below our estimate of fair value (MYR1.19)

Significantly Below Fair Value: RHONEMA is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Future Growth

How is Rhone Ma Holdings Berhad forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-3.7%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: RHONEMA's earnings are forecast to decline over the next 3 years (-3.7% per year).

Earnings vs Market: RHONEMA's earnings are forecast to decline over the next 3 years (-3.7% per year).

High Growth Earnings: RHONEMA's earnings are forecast to decline over the next 3 years.

Revenue vs Market: RHONEMA's revenue (4.1% per year) is forecast to grow slower than the MY market (5.3% per year).

High Growth Revenue: RHONEMA's revenue (4.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: RHONEMA's Return on Equity is forecast to be low in 3 years time (7.1%).


Discover growth companies

Past Performance

How has Rhone Ma Holdings Berhad performed over the past 5 years?

Past Performance Score

4/6

Past Performance Score 4/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-5.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: RHONEMA has high quality earnings.

Growing Profit Margin: RHONEMA's current net profit margins (6.6%) are higher than last year (5.3%).


Past Earnings Growth Analysis

Earnings Trend: RHONEMA's earnings have declined by 5% per year over the past 5 years.

Accelerating Growth: RHONEMA's earnings growth over the past year (46.6%) exceeds its 5-year average (-5% per year).

Earnings vs Industry: RHONEMA earnings growth over the past year (46.6%) exceeded the Pharmaceuticals industry 21.4%.


Return on Equity

High ROE: RHONEMA's Return on Equity (8.3%) is considered low.


Discover strong past performing companies

Financial Health

How is Rhone Ma Holdings Berhad's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: RHONEMA's short term assets (MYR106.2M) exceed its short term liabilities (MYR25.1M).

Long Term Liabilities: RHONEMA's short term assets (MYR106.2M) exceed its long term liabilities (MYR27.0M).


Debt to Equity History and Analysis

Debt Level: RHONEMA has more cash than its total debt.

Reducing Debt: RHONEMA's debt to equity ratio has increased from 4.6% to 20.3% over the past 5 years.

Debt Coverage: RHONEMA's debt is well covered by operating cash flow (38.8%).

Interest Coverage: RHONEMA's interest payments on its debt are well covered by EBIT (14.9x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Rhone Ma Holdings Berhad current dividend yield, its reliability and sustainability?

Dividend Score

2/6

Dividend Score 2/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


2.90%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: RHONEMA's dividend (2.9%) is higher than the bottom 25% of dividend payers in the MY market (2%).

High Dividend: RHONEMA's dividend (2.9%) is low compared to the top 25% of dividend payers in the MY market (4.82%).


Stability and Growth of Payments

Stable Dividend: RHONEMA has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: RHONEMA has only been paying a dividend for 5 years, and since then payments have fallen.


Earnings Payout to Shareholders

Earnings Coverage: With its reasonably low payout ratio (34.5%), RHONEMA's dividend payments are well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its high cash payout ratio (129.2%), RHONEMA's dividend payments are not well covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

7.3yrs

Average board tenure


CEO

I-Ie Lim (51 yo)

no data

Tenure

RM835,459

Compensation

Dr. Ban Keong Lim, also known as I-Ie, serves as Group Managing Director of Rhone Ma Holdings Berhad and has been its Executive Director since April 1, 2015. Dr. Lim is responsible for the overall manageme...


CEO Compensation Analysis

Compensation vs Market: I-Ie's total compensation ($USD188.16K) is above average for companies of similar size in the MY market ($USD112.38K).

Compensation vs Earnings: I-Ie's compensation has increased by more than 20% in the past year.


Board Members

Experienced Board: RHONEMA's board of directors are considered experienced (7.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.1%.


Top Shareholders

Company Information

Rhone Ma Holdings Berhad's employee growth, exchange listings and data sources


Key Information

  • Name: Rhone Ma Holdings Berhad
  • Ticker: RHONEMA
  • Exchange: KLSE
  • Founded: 2000
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: RM152.646m
  • Shares outstanding: 221.23m
  • Website: https://www.rhonema.com

Number of Employees


Location

  • Rhone Ma Holdings Berhad
  • Lot 18A & 18B
  • Jalan 241
  • Petaling Jaya
  • Selangor
  • 46100
  • Malaysia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/12 00:00
End of Day Share Price2022/08/11 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.